Shares of Editas Medicine EDIT gained 4.2% on Monday after the company announced updated safety and efficacy data from the ...
Though he doesn't remember it, Branden Baptiste had his first sickle cell crisis at age 2. Through elementary school, he was ...
Though he doesn't remember it, Branden Baptiste had his first sickle cell crisis at age 2. Through elementary school, he was ...
J&J aims to expand Darzalex's use even further in the blood cancer, while Merck & Co. and Novo Nordisk presented at ASH ...
Research from Duke-NUS Medical School has revealed that fetuses are not as defenseless as once thought; they can actually ...
Beam Therapeutics (BEAM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Yanan Zhu ...
When you give to Light Up A Lawn, Light Up A Life, you are supporting programs like Nationwide Children's cutting-edge gene ...
Beam Therapeutics Inc. (NASDAQ:BEAM) revealed new safety and efficacy data from its BEACON Phase 1/2 trial of BEAM-101 in ...
MiNA Therapeutics Limited, the pioneer in small activating RNA (RNAa) therapeutics, today presented new pre-clinical data for its lead RNA activation program for the treatment of sickle cell disease, ...
The latest announcement is out from Beam Therapeutics ( (BEAM) ).